Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Nasopharyngeal Carcinoma 1

Interventions

pembrolizumab 84Cisplatin 73Cetuximab 54Radiotherapy 41Nivolumab 31Radiotherapy, Intensity-Modulated 26Docetaxel 26Fluorouracil 23Cyclophosphamide 23Paclitaxel 22fludarabine 19Radiation 18Gemcitabine 18Carboplatin 18Magnetic Resonance Spectroscopy 16Erlotinib Hydrochloride 16durvalumab 15atezolizumab 13fludarabine phosphate 10Radiosurgery 10Specimen Handling 9Interleukin-2 9Drug Therapy 9Biopsy 9130-nm albumin-bound paclitaxel 9budigalimab 8Ipilimumab 8Bortezomib 8tremelimumab 7toripalimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × fosaprepitant × Head & Neck × Clear all
NCT04636632 2022-11-07

Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 1 Completed
100 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡